Lyon, Paris, France - 20th October 2022 - 6 pm CEST - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates
AMF-regulated(1) Adbio partners, an investment company dedicated to life sciences, has welcomed Inserm Transfert, a private subsidiary of the French National Institute of Health and Medical Research (Inserm) as an investor in its AFB Fund II. Click to read more.
LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of